logo

For the Inventor, By the Inventor

Beijing, China

Qing Ge

This inventor holds 6 USPTO granted patents. Top assignees: Somagenics, Inc., Avi Biopharma, Inc., M.i.t.. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qing Ge. Retrieved from https://idiyas.com/inventor/qing-ge-a3b2qp90

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 18(Granted Patents)


Location History:

  • Santa Cruz, CA (US) (2012 - 2014)
  • Beijing, CN (2014 - 2020)

Company Filing History:

goldMedal5 out of 15 
 
Somagenics, Inc.
 patents
silverMedal1 out of 50 
 
Avi Biopharma, Inc.
 patents
bronzeMedal1 out of 10 
 
M.i.t.
 patents
where one patent can have more than one assignee

Years Active: 2012-2020

Loading Chart...
6 patents (USPTO):Explore Patents
1. 10870850 - Chemical modification of short small hairpin RNAs for inhibition of gene expression (2020-12-22),
2. 9816091 - Chemical modification of short small hairpin RNAs for inhibition of gene expression (2017-11-14),
3. 8871730 - Chemical modification of short small hairpin RNAs for inhibition of gene expression (2014-10-28),
4. 8779115 - Short hairpin RNAs for inhibition of gene expression (2014-07-15),
5. 8357664 - Antisense antiviral compound and method for treating influenza viral infection (2013-01-22),
6. 8283460 - Short hairpin RNAs for inhibition of gene expression (2012-10-09),

Title: Unveiling the Innovations of Inventor Qing Ge from Beijing

Introduction: Qing Ge, a talented inventor hailing from Beijing, CN, has made significant contributions to the field of gene silencing through his groundbreaking patents and research endeavors.

Latest Patents: Among his notable inventions are advancements in the chemical modification of short small hairpin RNAs for the inhibition of gene expression. These innovations focus on enhancing the efficacy and stability of RNAi agents used in gene silencing applications. The chemically modified RNAi agents developed by Qing Ge exhibit reduced immunostimulatory activity and increased serum stability, offering promising prospects in the realm of pharmaceutical compositions and gene therapy kits.

Career Highlights: Qing Ge has a remarkable portfolio of six patents, showcasing his expertise in molecular biology and biotechnology. His dedication to refining RNAi technologies underscores his commitment to driving innovation in the life sciences industry.

Collaborations: Throughout his career, Qing Ge has collaborated with esteemed professionals in the field, including colleagues like Brian H Johnston and Heini Ilves. These collaborative efforts have undoubtedly enriched the research landscape and promoted knowledge exchange within the scientific community.

Conclusion: In conclusion, Qing Ge's trailblazing work in the realm of gene silencing and RNAi technologies exemplifies his unwavering dedication to advancing scientific knowledge and pioneering new frontiers in biomedicine. His inventive spirit and collaborative approach underscore the importance of fostering synergistic partnerships to drive meaningful innovation in the ever-evolving field of biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…